#United States #Philadelphia #financial results #Q3 2025 #FMC Corporation

FMC Corporation Reports Third Quarter Results

On October 29, 2025, FMC Corporation (NYSE: FMC) released its financial results for the third quarter of 2025, highlighting notable changes that have impacted its performance. The company's revenue reached $542 million, marking a drastic 49% decline compared to the same quarter in the previous year. This reduction was primarily attributed to substantial one-time commercial actions taken in India as part of their strategy to position the business for sale.

Excluding the impacts of the India operations, FMC's revenue stood at $961 million, down 10% year-over-year, and organic revenue declined by 11%. These numbers reflect both lower pricing in certain markets and challenges posed by competitive pressures, particularly from generic products in Latin America and Asia.

The report showed a consolidated GAAP net loss of $569 million, a sharp drop from the previous year’s performance which had recorded a profit. This significant decline was mainly driven by charges related to the India business, including a write-down of assets as they aim for a sale. On a more positive note, the adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rose by 17% to $236 million, suggesting some operational resilience amid the turmoil.

FMC's adjusted earnings per diluted share improved to $0.89, a 30% increase from Q3 2024, showcasing the company's efforts to streamline operations. CEO Pierre Brondeau commented on the financial report, noting that while the sales figures dropped dramatically due to the temporary challenges in India, similar performance metrics excluding India showed a smaller decline of just 4%.

The challenges faced by FMC were evident across various regions. North America did see a 4% increase in sales, chiefly driven by greater volumes in its growth portfolio and the successful branded product Rynaxypyr®. However, Latin American revenues fell by 8% year-over-year, hindered by competitive price pressures and decreased customer liquidity in countries like Brazil and Argentina. Sales in Asia (excluding India) slumped by nearly 47%, primarily due to the absence of India revenues and a general downturn in volumes as well as pricing driven down by generic competition. Conversely, the Europe, Middle East, and Africa (EMEA) region did post an 11% revenue increase, buoyed by strong performance in the growth portfolio.

Looking ahead, FMC provided an updated outlook for the full year, lowering their revenue expectations to a range between $3.92 billion and $4.02 billion. This marks a 7% decrease from previous projections. Additionally, they indicated an adjusted EBITDA forecast of between $830 million and $870 million, reflecting a 6% decline compared to prior years. These adjustments are primarily due to the anticipated impacts of the reduced role of the India operations in their overall business.

In light of the current financial landscape, FMC's Board of Directors also decided to cut dividends to $0.08 per share, positioning the company to prioritize debt reduction and cash generation as it navigates through these challenging conditions. The company is actively redesigning its operational footprint to better align with its strategic goals while optimizing production costs, especially following the anticipated divestiture of its India business, which has a fair value currently estimated to be around $450 million.

FMC's ongoing adjustment strategies reflect their commitment to maintaining a competitive edge in the agricultural sector despite a difficult quarter. As they move forward, the company aims to leverage their new active ingredients, which have seen significant growth in recent months, to spearhead recovery and fortify their market presence. Stakeholders will be keen to see how these initiatives unfold and the impact they will have on the company’s long-term profitability.